Search results
Results from the WOW.Com Content Network
More must be done to see whether existing drugs could help to tackle dementia, scientists have said after finding that a number of common treatments may affect a person’s risk. While some new ...
Stimulants in general and various dementia treatments [10] or other neurological therapies [11] may affect cognition. Neuroenhancement may also occur from: mood ('mood enhancement') [12] motivation [13] sociability (e.g., talking-related or empathy) [14] creativity [13] cognitive endurance [15] psychological resilience [16]
Scientists hope to investigate whether common drugs could be used to help fight dementia after ibuprofen and some prescription antibiotics, antivirals and vaccines were associated with a reduced ...
Psychological therapies for dementia are starting to gain some momentum. [ when? ] Improved clinical assessment in early stages of Alzheimer's disease and other forms of dementia , increased cognitive stimulation of the elderly, and the prescription of drugs to slow cognitive decline have resulted in increased detection in the early stages.
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...
A recent study found that a class of medications called SGLT-2 inhibitors—which does not include Ozempic or similar drugs like Zepbound—significantly lowered the risk of dementia in people ...
Vistaril (hydroxyzine) – an antihistamine for the treatment of itches and irritations, an antiemetic, as a weak analgesic, an opioid potentiator, and as an anxiolytic; Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo
Nicergoline, sold under the brand name Sermion among others, is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Internationally it has been used for frontotemporal dementia as well as early onset in Lewy body dementia and Parkinson's dementia.